Protagonist Therapeutics PTGX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -192.4%-205pp | -343.6%-402pp | 9.1%— | 11.5%— | 13.1%— | |
| Net margin | -154.9%-182pp | -282.8%-346pp | 21.9%— | 24.9%— | 27%— | |
| EBITDA margin | -190.4%-204pp | -340.9%-399pp | 9.6%— | 11.9%— | 13.5%— | |
| Returns | ||||||
| Return on equity | -17.1%-26.1pp | -20.2%-74.6pp | 7.8%— | 8.6%— | 9%— | |
| Return on assets | -15.9%-24.1pp | -18.4%-68.3pp | 7%— | 7.8%— | 8.2%— | |
| Return on invested capital | -27.6%-33.2pp | -29.1%-96.4pp | 3.8%— | 6.6%— | 5.6%— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.1×-0.7× | 0.3×-0.4× | 0.3×-0.4× | 0.3×-0.4× | |
| Liquidity | ||||||
| Current ratio | 17.8×+0.5× | 12.7×+0.2× | 13×+2.4× | 17×+3.2× | 17.3×+1.5× | |
| Quick ratio | 17.8×+0.5× | 12.7×+0.2× | 13×+2.4× | 17×+3.2× | 17.3×+1.5× | |
| Cash ratio | 5.6×+1.6× | 2.8×+0.8× | 2.5×-0.4× | 4.7×-3.8× | 4×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $9.30-15.0% | $9.67-6.8% | $10.12+17.5% | $10.52+19.1% | $10.94+24.2% | |
| Valuation | ||||||
| Market capitalization | $6.73B+127% | $5.46B+137% | $4.13B+49.8% | $3.33B+57.8% | $2.97B+68.6% | |
| Enterprise value | $6.54B+130% | $5.34B+141% | $4.03B+52.7% | $3.17B+79.7% | $2.84B+78.8% | |
| Price / sales | 90.8×+76.5× | 118.7×+113× | 19.8×+11.2× | 15.9×+9.3× | 14.3×+8.7× | |
| Price / book | 10.3×+6.0× | 8.9×+5.5× | 6.4×+1.2× | 5×+1.1× | 4.3×+1.2× | |
| EV / sales | 88.3×+74.7× | 116.1×+111× | 19.3×+11.1× | 15.2×+9.6× | 13.7×+8.6× | |
| Earnings yield | -1.7%-3.6pp | -2.4%-14.3pp | 1.1%— | 1.6%— | 1.9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Protagonist Therapeutics's ratios come from?
- Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
